Alligator Bioscience

Alligator Bioscience AAQS

The The AAQS of Alligator Bioscience (ATORX.ST) as of Oct 18, 2026 is 2. In the previous year, The AAQS was 2.00 — a change of 0.00% (lower).

AAQS

2

YoY

0.00%

Last updated:

Alligator Bioscience has a current AAQS of 2.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Alligator Bioscience in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Alligator Bioscience AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
2.00 SEK
Jan 1, 2019
2.00 SEK
Jan 1, 2020
2.00 SEK
Jan 1, 2021
2.00 SEK
Jan 1, 2022
2.00 SEK
Jan 1, 2023
2.00 SEK
Jan 1, 2024
2.00 SEK
Jan 1, 2025
2.00 SEK
The Alligator Bioscience AAQS history
YEARAAQSYoY
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
2—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Alligator Bioscience Stock analysis

What does Alligator Bioscience do? Alligator Bioscience AB, headquartered in Lund, Sweden, is a biotechnology company specializing in the development of antibody-based immunotherapies for cancer treatment. The company utilizes its ALLIGATOR-GOLD antibody library and FIND optimization technology to create tumor-directed therapies, including mono- and bispecific antibodies. With a pipeline featuring three preclinical-stage projects—ADC-1013, ATOR-1015, and ATOR-1016—the firm focuses on innovative cancer immunotherapies. Listed on 23 November 2016, it employs 43 full-time staff. Alligator Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alligator Bioscience stock

The AAQS of Alligator Bioscience is 2 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Alligator Bioscience since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Quality — Alligator Bioscience

AAQSPiotroski F-ScoreAltman Z-ScoreGraham NumberRule of 40

All Key Metrics — Alligator Bioscience